Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: An actual challenge

Carlo G. Tocchetti, Gianluca Ragone, Carmela Coppola, Domenica Rea, Giovanna Piscopo, Stefania Scala, Claudia De Lorenzo, Rosario V. Iaffaioli, Claudio Arra, Nicola Maurea

Research output: Contribution to journalArticle

Abstract

The antibody trastuzumab, targeted to inhibit the signalling of ErbB2, a tyrosine kinase receptor overexpressed in 2030 of breast cancers, improves the prognosis in women affected by this tumour, but produces cardiotoxicity, since ErbB2 is also involved in myocardial homeostasis. In this review, we discuss the pathophysiology of trastuzumab cardiomyopathy and the complex interplay between ErbB2 inhibition and anthracyclines, and we focus on the actual challenges of detecting, monitoring, and managing trastuzumab cardiotoxicity: the research of new, sensitive markers of early trastuzumab toxicity, before the ejection fraction is reduced, is an active field of research.

Original languageEnglish
Pages (from-to)130-137
Number of pages8
JournalEuropean Journal of Heart Failure
Volume14
Issue number2
DOIs
Publication statusPublished - Feb 2012

Keywords

  • Anthracyclines
  • Biomarkers
  • Ejection fraction
  • ErbB2
  • New echocardiographic techniques
  • Trastuzumab cardiomyopathy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: An actual challenge'. Together they form a unique fingerprint.

  • Cite this